Special clinical interest in breast, prostate, kidney and bladder cancer
Dr Mark Tuthill is a Consultant Medical Oncologist who specialises in the treatment of early and recurrent cancers of the breast, prostate, kidney and bladder. In 2015, he was appointed Consultant Medical Oncologist at Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, where, in addition, he acts as Chief and Principal investigator on a number of clinical trials.
Dr Tuthill focusses on providing a patient centred approach to treatment ensuring clear communication, evidence-based therapies and molecularly targeted therapies to enable personalised medicine. Treatments can include the use of chemotherapy, hormone therapy, immunotherapy, or cancer growth inhibitors and experimental treatments given as part of clinical trials.
Dr Tuthill originally qualified from University College London and trained in Medical Oncology in London. He holds a PhD in Tumour Immunology from Imperial College London and regularly presents his research at national and international conferences. Dr Tuthill is a clinical ambassador for UCARE (Urology Cancer Research and Education), an independent charity raising funds for research into prostate and bladder cancer and is a member of The Association of Cancer Physicians.
Dr Tuthill’s research interests include cancer vaccines, tumour immunology, cancer-growth inhibitors, and novel therapeutic drug combinations for the treatment of cancer. He is a Chief, principal investigator or sub-investigator for early and late phase clinical trials in tumour types including breast cancer, urological cancers and other tumour types.
- The Churchill Hospital
- Oxford University Hospitals NHS Foundation Trust